ArticleCancer microenvironment : official journal of the International Cancer Microenvironment Society2008
Bone marrow microenvironment and tumor progression.
Article in Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 65 citations in OpenAlex.
- Development and verification of a competing risk model for forecasting cancer-specific survival in malignant bone tumor patients: an analysis of SEER database.Translational cancer research · 2026Article
- Preclinical evaluation of CPL423: a novel potent small-molecule inhibitor of TAM family and FLT3 kinase for cancer therapy.Frontiers in pharmacology · 2026Article
- Global trends in breast cancer bone metastasis research (2009-2024): a bibliometric and visual analysis of hotspots and future directions.Discover oncology · 2025Article
- Combination of low-intensity pulsed ultrasound irradiating immune organs with immune checkpoint blockade augments systemic anti-tumor immunity on low tumor burden 4T-1 breast cancer.Cancer immunology, immunotherapy : CII · 2025Article
- Resident stroma-secreted chemokine CCL2 governs myeloid-derived suppressor cells in the tumor microenvironment.JCI insight · 2022Article
- Article
- Cancer-Associated Fibroblasts in the Breast Tumor Microenvironment.Journal of mammary gland biology and neoplasia · 2021Review
- Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases.Molecules (Basel, Switzerland) · 2021Review
- A Rare Case of Metastasis to the Mandible from the Thyroid Gland: a Case Report and Literature Review.Indian journal of surgical oncology · 2019Article
- Review
- Article
- Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment.Oncotarget · 2018Review
- A New Chapter for Mesenchymal Stem Cells: Decellularized Extracellular Matrices.Stem cell reviews and reports · 2017Review
- The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.Current osteoporosis reports · 2016Review
- Targeted Proapoptotic Peptides Depleting Adipose Stromal Cells Inhibit Tumor Growth.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- Malignant Transformation in Glioma Steered by an Angiogenic Switch: Defining a Role for Bone Marrow-Derived Cells.Cureus · 2016Review
- Bone metastasis and the metastatic niche.Journal of molecular medicine (Berlin, Germany) · 2015Review
- The bone marrow metastasis niche in retinoblastoma.Cellular oncology (Dordrecht, Netherlands) · 2015Review
- CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.Hepatology (Baltimore, Md.) · 2015Article
- CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence.Oncology letters · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
The bone marrow constitutes an unique microenvironment for cancer cells in three specific aspects. First, the bone marrow actively recruits circulating tumor cells where they find a sanctuary rich in growth factors and cytokines that promote their proliferation and survival. When in the bone marrow, tumor cells profoundly affect the homeostasis of the bone and the balance between osteogenesis and osteolysis. As a consequence, growth and survival factors normally sequestered into the bone matrix are released, further fueling cancer progression. Second, tumor cells actively recruit bone marrow-derived precursor cells into their own microenvironment. When in the tumors, these bone marrow-derived cells contribute to an inflammatory reaction and to the formation of the tumor vasculature. Third, bone marrow-derived cells can home in distant organs, where they form niches that attract circulating tumor cells. Our understanding of the contribution of the bone marrow microenvironment to cancer progression has therefore dramatically improved over the last few years. The importance of this new knowledge cannot be underestimated considering that the vast majority of cancer treatments such as cytotoxic and myeloablative chemotherapy, bone marrow transplantation and radiation therapy inflict a trauma to the bone marrow microenvironment. How such trauma affects the influence that the bone marrow microenvironment exerts on cancer is still poorly understood. In this article, the reciprocal relationship between the bone marrow microenvironment and tumor cells is reviewed, and its potential impact on cancer therapy is discussed.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.